Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy

European Journal of Pharmacology

Volumn 595, Issue 1-3, 2008, Pages 13-21

  Luszczki, Jarogniew J ^a,b   Ratnaraj, Neville ^c   Patsalos, Philip N ^c   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Drug interaction; Gabapentin; Isobolographic analysis; Maximal electroshock seizure threshold test; Pentylenetetrazole induced seizure test; Vigabatrin

Indexed keywords

GABAPENTIN; PENTETRAZOLE; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENTIATION; ELECTRIC SHOCK; EPILEPSY; EXPERIMENTAL MODEL; GRIP STRENGTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SEIZURE THRESHOLD;

AMINES; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BRAIN; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; MUSCLE STRENGTH; PENTYLENETETRAZOLE; PSYCHOMOTOR PERFORMANCE; SEIZURES; VIGABATRIN;

EID: 52049105361     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.051     Document Type: Article

References (65)

1. Abe M., and Matsuda M. On the existence of two GABA pools associated with newly synthesized GABA and with newly taken up GABA in nerve terminals. Neurochem. Res. 8 (1983) 563-573
2. Berenbaum M.C. What is synergy? Pharmacol. Rev. 41, 93-141. Erratum published in 1989. Pharmacol. Rev. 41 (1989) 422
3. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. (Basel) 3 (1960) 81-84
4. Borowicz K.K., Luszczki J.J., and Czuczwar S.J. Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice. Epilepsia 45 (2004) 1176-1183
5. Brodie M.J., and Mumford J.P. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res. 34 (1999) 199-205
6. Brodie M.J., and Yuen A.W. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 26 (1997) 423-432
7. Czuczwar S.J., and Patsalos P.N. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 15 (2001) 339-350
8. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., and Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41 (2000) 1364-1374
9. Elwes R.D., and Binnie C.D. Clinical pharmacokinetics of newer antiepileptic drugsLamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin. Pharmacokinet. 30 (1996) 403-415
10. Ferrie C.D., Robinson R.O., Knott C., and Panayiotopoulos C.P. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand. 91 (1995) 200-202
11. 2δ subunit of calcium channel. J. Biol. Chem. 271 (1996) 5768-5776
12. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 22 (2000) 75-80
13. Gidal B.E., DeCerce J., Bockbrader H.N., Gonzalez J., Kruger S., Pitterle M.E., Rutecki P., and Ramsay R.E. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31 (1998) 91-99
14. Glantz S.A., and Slinker B.K. Primer of applied regression and analysis of variance. second ed. (2001), McGraw-Hill Inc., New York
15. Goldlust A., Su T.Z., Welty D.F., Taylor C.P., and Oxender D.L. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res. 22 (1995) 1-11
16. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47 (1995) 331-385
17. Guerrini R., Belmonte A., and Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 39 Suppl 3 (1998) S2-S10
18. Jensen A.A., Mosbacher J., Elg S., Lingenhoehl K., Lohmann T., Johansen T.N., Abrahamsen B., Mattsson J.P., Lehmann A., Bettler B., and Brauner-Osborne H. The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol. Pharmacol. 61 (2002) 1377-1384
19. Jung M.J., Lippert B., Metcalf B.W., Bohlen P., and Schechter P.J. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J. Neurochem. 29 (1977) 797-802
20. Kimball A.W., Burnett W.T., and Doherty D.G. Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat. Res. 7 (1957) 1-12
21. de Krom M.C., Verduin N., Visser E., Kleijer M., Scholtes F., and De Groen J.H. Status epilepticus during vigabatrin treatment: a report of three cases. Seizure 4 (1995) 159-162
22. Leach J.P. Antiepileptic drugs: safety in numbers?. Seizure 9 (2000) 170-178
23. Leach J.P., and Brodie M.J. Synergism with GABAergic drugs in refractory epilepsy. Lancet 343 (1994) 1650
24. Lippert B., Metcalf B.W., Jung M.J., and Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur. J. Biochem. 74 (1977) 441-445
25. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
26. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3 (1953) 285-290
27. Löscher W., and Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2 (1988) 145-181
28. Löscher W., and Wauquier A. Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res. Suppl 11 (1996) 61-65
29. Löscher W., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8 (1991) 79-94
30. Löscher W., Hönack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 8 (1991) 171-189
31. Löscher W. A comparative study of the pharmacology of inhibitors of GABA-metabolism. Naunyn-Schmiedeberg's Arch. Pharmacol. 315 (1980) 119-128
32. Lücke A., Musshoff U., Kohling R., Osterfeld M., Mayer T., Wolf P., Schutte W., and Speckmann E.J. Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy. Br. J. Pharmacol. 124 (1998) 370-376
33. Luszczki J.J., and Czuczwar S.J. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. Epilepsy Res. 56 (2003) 27-42
34. Luszczki J.J., and Czuczwar S.J. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 434-446
35. Luszczki J.J., and Czuczwar S.J. Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Naunyn-Schmiedeberg's Arch. Pharmacol. 372 (2005) 41-54
36. Luszczki J.J., and Czuczwar S.J. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn-Schmiedeberg's Arch. Pharmacol. 374 (2006) 51-64
37. Luszczki J.J., and Czuczwar S.J. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 (2007) 529-538
38. Luszczki J.J., Andres-Mach M.M., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 48 (2007) 806-815
39. Luszczki J.J., Borowicz K.K., Swiader M., and Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44 (2003) 489-499
40. Luszczki J.J., Czuczwar M., Kis J., Krysa J., Pasztelan I., Swiader M., and Czuczwar S.J. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44 (2003) 1001-1011
41. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedeberg's Arch. Pharmacol. 373 (2006) 169-181
42. Luszczki J.J., Swiader M., Parada-Turska J., and Czuczwar S.J. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 28 (2003) 1817-1830
43. Luszczki J.J., Wojcik-Cwikla J., Andres M.M., and Czuczwar S.J. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 30 (2005) 958-973
44. Nielsen E.B., Suzdak P.D., Andersen K.E., Knutsen L.J., Sonnewald U., and Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur. J. Pharmacol. 196 (1991) 257-266
45. Parker D.A.S., Ong J., Marino V., and Kerr D.I.B. Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. Eur. J. Pharmacol. 495 (2004) 137-143
46. Patsalos P.N. The pharmacokinetic characteristics of levetiracetam. Methods Find. Exp. Clin. Pharmacol. 25 (2003) 123-129
47. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43 (2004) 707-724
48. Patsalos P.N. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev. Contemp. Pharmacother. 13 (2004) 1-168
49. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2 (2003) 347-356
50. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol. Scand., Suppl. 162 (1995) 31-34
51. Perucca E., Gram L., Avanzini G., and Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39 (1998) 5-17
52. Pisani F., Oteri G., Russo M.F., Di Perri R., Perucca E., and Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40 (1999) 1141-1146
53. 5]enkephalin: a synergistic interaction. Eur. J. Pharmacol. 179 (1990) 463-468
54. Rambeck B., Sprecht U., and Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin. Pharmacokinet. 31 (1996) 309-324
55. Ratnaraj N., and Patsalos P.N. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther. Drug Monit. 20 (1998) 430-434
56. Reutens D.C., Duncan J.S., and Patsalos P.N. Disabling tremor after lamotrigine with sodium valproate. Lancet 342 (1993) 185-186
57. Rey E., Pons G., and Olive G. Vigabatrin. Clinical pharmacokinetics. Clin. Pharmacokinet. 23 (1992) 267-278
58. Rowan A.J., Meijer J.W., de Beer-Pawlikowski N., van der Geest P., and Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch. Neurol. 40 (1983) 797-802
59. Stephen L.J., Sills G.J., and Brodie M.J. Lamotrigine and topiramate may be a useful combination. Lancet 351 (1998) 958-959
60. Stolarek I., Blacklaw J., Forrest G., and Brodie M.J. Vigabatrin and lamotrigine in refractory epilepsy. J. Neurol. Neurosurg. Psychiatry 57 (1994) 921-924
61. Striano P., Coppola A., Madia F., Pezzella M., Ciampa C., Zara F., and Striano S. Life-threatening status epilepticus following gabapentin administration in a patient with benign adult familial myoclonic epilepsy. Epilepsia 48 (2007) 1995-1998
62. Tallarida R.J. Drug synergism and dose-effect data analysis (2000), Chapman and Hall/CRC, Boca Raton, FL
63. Tallarida R.J., Stone D.J., and Raffa R.B. Efficient designs for studying synergistic drug combinations. Life Sci. 61 (1997) PL417-PL425
64. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., Dooley D.J., Boden P., and Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29 (1998) 233-249
65. Thomas P., Valton L., and Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 129 Pt 5 (2006) 1281-1292